Browse drugs

…ater cumulative time in LLDAS over 12 months is achieved in the rituximab group compared with placebo. We will also evaluate secondary ou…

… associated with earlier flare occurrence (log-rank p = 0.002). Hydroxychloroquine (HCQ) tapering or discontinuation invariably preceded moderate-…

…Objectives Hydroxychloroquine (HCQ) is a cornerstone therapy in systemic lupus erythematosus …

…CR 2019, SLICC and/or ACR 1997 diagnostic criteria treated with Belimumab in monotherapy. Data were collected from medical records of SLE…

…prine (16%), methotrexate (9%), and mycophenolate mofetil (9%). Rituximab was used in 7% of severe or treatment-resistant patients.Conclu…

…nts were taking a mean of 2.2 SLE medications; 98% had received hydroxychloroquine and 80% at least one immunosuppressant (including biologics). C…

…ian annual cost of 204.9 USD. 88% reported OOP for medications, hydroxychloroquine being the most frequently self-purchased drug (76%). The median…

…endent clinical trials: BEAT-lupus and CALIBRATE both comparing belimumab after rituximab vs. rituximab. We further evaluated its potenti…

…an age 31 years; median disease duration 9 years), 94% received hydroxychloroquine and 70% received immunosuppressants. Of those tapering PDN (n=7…

…yopathy (HF/CM) and assessed whether initiation and duration of hydroxychloroquine (HCQ) influence this risk.Methods This population-based cohort …

…disease in the peripartum period. Uptake of SLE treatments (eg. hydroxychloroquine), remain suboptimal during pregnancy. We examined medication us…

…umab (360 mg intravenously every 3 weeks) and cohort B received hydroxychloroquine (600 mg orally two times a day). The primary endpoint was safet…